Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_4
4
50%
Ph phase_2
2
25%
Ph phase_3
1
13%

Phase Distribution

0

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
4(57.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(5)

Detailed Status

unknown5
Completed1
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (28.6%)
Phase 31 (14.3%)
Phase 44 (57.1%)

Trials by Status

completed113%
terminated113%
unknown563%
not_yet_recruiting113%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_4

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

NCT05071482
completedphase_2

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

NCT05433532
unknown

Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib

NCT04681820
unknownphase_4

The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

NCT04933526
not_yet_recruitingphase_4

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT05367765
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05071482Phase 4

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

Terminated
NCT05433532Phase 2

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Completed
NCT04681820

Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib

Unknown
NCT04933526Phase 4

The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

Unknown
NCT05367765Phase 4

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Not Yet Recruiting
NCT04375683Phase 3

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

Unknown
NCT04677439Phase 4

Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

Unknown
NCT01503502Phase 2

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8